Genital herpes, caused by herpes simplex virus type-2 (HSV-2), is a recurrent, lifelong disease affecting tens of millions of people in the USA alone. HSV-2 can be treated therapeutically with acyclovir (ACV) and its derivatives; however, no treatment can prevent HSV reactivation. Novel topical anti-HSV microbicides are much needed to reduce HSV-2 transmission and to treat primary or reactivated infections, especially for ACV- resistant strains. Peptide- conjugated phosphorodiamidate morpholino oligomers (PPMOs) are single-stranded DNA analogues that enter cells readily and can reduce target gene expression through steric blockage of complementary messenger RNA (mRNA).
Methods
We investigated the antiviral activities of PPMOs targeted to the translation start-site regions of the mRNA for two HSV-2 immediate early genes, immediate early protein (ICP)0 and ICP27, and two early genes, unique long gene (UL)30 and UL39.
Results
In cell cultures, PPMOs targeting ICP0 or ICP27 mRNA were found to be highly effective against two strains of HSV-2, one of which was ACV-resistant. In vivo, daily topical applications of up to 1 mM ICP27 PPMO caused no gross or microscopic damage to the genital tract of uninfected BALB/c mice or cotton rats. Cotton rats receiving topical application of ICP27 PPMO 24 h after HSV-2 inoculation showed a reduction in genital lesions and a 37.5% reduction in mortality at 14 days post-infection. Mice receiving topical application of 100 μM of an ICP27 and ICP0 PPMO combination before HSV-2 inoculation had no detectable viral replication in the genital tract at 3–5 days post-infection.
Conclusions
These results demonstrate that topically applied PPMOs hold promise as candidate antiviral microbicides against HSV-2 genital infection.
References
1.
XuF., MarkowitzL.E., GottliebS.L., BermanS.M.Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States.Am J Obstet Gynecol2007; 196: 43.e1–43.e6.
2.
XuF., SternbergM.R., KottiriB.J.Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.JAMA2006; 296: 964–973.
3.
RoizmanB., KnipeD.M.Herpes simplex viruses and their replication. In KnipeD.M., HowleyP.M. (Editors). Fields Virology. 4th ed.Philadelphia: Lippincott, Williams and Wilkins2001; pp. 2399–2459.
4.
KimH.N., MeierA., HuangM.L.Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.J Infect Dis2006; 194: 420–427.
5.
WaldA., ZehJ., SelkeS.Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.N Engl J Med2000; 342: 844–850.
6.
WolffM.H., SchmittJ., RahausM., DuddaH., HatzmannW.Clinical and subclinical reactivation of genital herpes virus.Intervirology2002; 45: 20–23.
7.
SummertonJ., WellerD.Morpholino antisense oligomers: design, preparation, and properties.Antisense Nucleic Acid Drug Dev1997; 7: 187–195.
8.
SteinD., FosterE., HuangS.B., WellerD., SummertonJ.A specificity comparison of four antisense types: morpholino, 2’-O-methyl RNA, DNA, and phosphorothioate DNA.Antisense Nucleic Acid Drug Dev1997; 7: 151–157.
9.
MoultonH.M., NelsonM.H., HatlevigS.A., ReddyM.T., IversenP.L.Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.Bioconjug Chem2004; 15: 290–299.
10.
DeasT.S., Binduga-GajewskaI., TilgnerM.Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.J Virol2005; 79: 4599–4609.
11.
SteinD.A.Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers.Curr Pharm Des2008; 14: 2619–2634.
12.
ZhangY.J., WangK.Y., SteinD.A.Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.Antiviral Res2007; 73: 12–23.
13.
ZhangY.J., BonaparteR.S., PatelD., SteinD.A., IversenP.L.Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.Mol Cancer Ther2008; 7: 712–720.
14.
Moerdyk-SchauweckerM., SteinD.A., EideK.Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27.Antiviral Res2009; 84: 131–141.
15.
CzartoskiT., LiuC., KoelleD.M., SchmechelS., KalusA., WaldA.Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman.J Clin Microbiol2006; 44: 1584–1586.
16.
AbesS., MoultonH.M., ClairP.Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.J Control Release2006; 116: 304–313.
YimK.C., CarrollC.J., TuyamaA.The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.J Virol2005; 79: 14632–14639.
19.
ChenJ., SilversteinS.Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression.J Virol1992; 66: 2916–2927.
20.
Sandri-GoldinR.M.The many roles of the regulatory protein ICP27 during herpes simplex virus infection.Front Biosci2008; 13: 5241–5256.
21.
ZheR., Mei-YingZ., KitazatoK.Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA.Arch Virol2008; 153: 1401–1406.
22.
PeymanA., HelsbergM., KretzschmarG., MagM., GrableyS., UhlmannE.Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1.Biol Chem Hoppe Seyler1995; 376: 195–198.
23.
ParrM.B., ParrE.L.Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes.J Virol1998; 72: 2677–2685.
24.
MahjoubS.B., GanleyJ.P., MisraR.P., LangfordM.P.Isolation of a herpes simplex virus type 2 that is retinovirulent in mice.Curr Eye Res1989; 8: 687–695.
25.
GershengornH.B., DarbyG., BlowerS.M.Predicting the emergence of drug-resistant HSV-2: new predictions.BMC Infect Dis2003; 3: 1.
